differentiatial grade were significant prognostic factors. Radical surgery and local destruction might have the similar effect in early stage patients. Triple combination treatments showed a superiority to others. The cut-off points of tumor size were 3cm and >7cm. The adjusted staging system was proved to be more accurate. Conclusion: Tumor size matters in the prognosis of MPM especially in early stages. The adjusted TNM staging system incorporating tumor size has better accuracy than the 8th edition. However, some stages had not been fully verified. More cases of early stages are warranted for essential revision.
< 0.001. Other factors showed no significant differences between the two groups. Overall clinical response (CR+PR) was 20% in group (1) versus 17.9 % in group (2). P¼0.7. There was a trend towards longer median PFS in young patients, (19.8 ± 8.4 versus 6.9 ± 1.4 months). p ¼ 0.09. The median OS of young patients is significantly longer (20.6± 6.3 months) than older patients (11.4 ± 3.6).p ¼ 0.05. Conclusion: Mesothelioma in the young adult is more sensitive to asbestos exposure, has better OS and likely a different disease entity which needs further studies to understand its underlying biological features.
P2.06-16 YB-1: An Important Driver of Mesothelioma Drug Resistance and a Potential Novel Therapeutic Target T. Johnson, 1 K. Schelch, 2 K. Sarun, 1 M. Williams, 1 Y.Y. Cheng, 1 A. Lasham, 3 G. Reid 4 1 Asbestos Diseases Research Institute, Sydney/AU, 2 Medical University of Vienna, Institute of Cancer Research, Vienna/AT, 3 University of Auckland, Auckland/NZ, 4 Concord Clinical School, the University of Sydney, Sydney/AU Background: Malignant pleural mesothelioma (MPM) is an aggressive malignancy and current therapy is essentially palliative. Novel therapy targets are urgently needed. YB-1 is a multifunctional oncoprotein associated with poor patient outcome and is related to increased chemoresistance in tumours including NSCLC. It is widely accepted that YB-1 plays a role in the cell growth of many cancers, and we recently confirmed this in MPM cells. Here, we begin to evaluate YB-1 as a therapeutic target in this disease. Method: YB-1 expression was determined by Western blot in MPM cell lines and their drug resistant sublines. Growth and colony formation assays were conducted after transfection with YB-1-or control-siRNA. These were also carried out in combination with cisplatin, gemcitabine or vinorelbine treatment. Apoptosis was assessed by PI and annexin V staining in YB-1 knockdown MPM cells. Migration of MPM cells was measured using videomicroscopy and manual cell tracking. Luciferase-expressing MPM cells transfected with YB-1-or control-siRNA were injected into female SCID mice (n¼10, intra-peritoneal injection). Tumour growth was monitored via luminescence by injecting luciferin (intra-peritoneal injection) and measuring bioluminescence on an In Vitro Imaging System (IVIS) once a week for 4 weeks. Tumour weight determined after humane euthanasia of animals at the termination of the experiment. Result: YB-1-siRNA significantly inhibited the growth of MPM cell lines in vitro and was overexpressed in MPM cells compared to the immortalised mesothelial cell line MeT-5A. Growth of MeT-5A and primary mesothelial cell lines was not affected significantly by YB-1 knockdown. Mice injected with YB-1 knockdown cells displayed significantly lower tumour burden, evidenced by bioluminescence in live mice using IVIS and lower tumour weight after harvest. TALI assays showed an increase in apoptotic cells after YB-1 siRNA transfection in vitro, and cells transfected with siRNA showed sensitisation to cisplatin and vinorelbine. YB-1 was expressed at higher levels, and higher migratory capacity was observed in drug resistant MPM cell lines compared to parental cell lines. Conclusion: These results highlight the importance of YB-1 in MPM biology both in vitro and in vivo. YB-1 knockdown inhibits growth via apoptosis, sensitises MPM cells to commonly prescribed drugs and contributes to a change in behaviour of drug resistant MPM cells. This project serves as a basis for the further investigation of YB-1 as a novel therapeutic target. Keywords: Y-box binding protein-1, Mesothelioma, drug resistance Background: Magnetic resonance imaging (MRI) of the chest is commonly employed for preoperative staging of patients with malignant pleural mesothelioma. Here we evaluate the accuracy of preoperative MRI for detection of diaphragmatic invasion in patients undergoing pleurectomy in a real-world setting. Method: All adult patients who had a MRI of the chest performed as part of routine preoperative staging with subsequent pleurectomy for malignant pleural mesothelioma during a 20-month interval were identified. Patients without available MRI imaging reports were excluded. MRI reports for each patient were reviewed by a thoracic radiologist for evidence of diaphragmatic invasion and correlated with intraoperative findings. The MRI images for those patients with discrepant readings between MRI exam and intraoperative findings of diaphragm invasion were directly reviewed by the radiologist to assess for technical aspects that may have contributed to limitations in imaging interpretation. Result: A total of 16 adult patients with MPM, 14 male and 2 female, had preoperative MRI examinations performed with reports that were available for review, noting that a subset of examinations were obtained at outside community imaging sites resulting in variability of the imaging techniques and scanner types. Five patients had suspected or definitive diaphragmatic invasion on MRI, all of which were confirmed at pleurectomy. However, 9 of the patients that were initially assessed by MRI as not having diaphragmatic invasion, were later found at surgery to have some degree of diaphragmatic invasion necessitating diaphragmatic repair or diaphragmatic graft placement. When MRI exams were analyzed from patients that had missed diaphragmatic invasion on MRI interpretation, technical parameters such as differences in study image acquisition and technical artifacts due to cardiac, aortic pulsation and respiration motion may have contributed to the lack of identification of diaphragmatic invasion. Conclusion: MRI for preoperative planning in patients with MPM may miss diaphragmatic invasion. Further study is needed to determine if technical factors may contribute to limitations in detection of diaphragmatic invasion in MPM with a goal to optimize and harmonize MRI imaging protocols for preoperative staging. Background: Pleurectomy/decortication (P/D) is an operation to dissect the entire visceral and parietal pleura. Chief complications are hemorrhage and prolonged air leak. To avoid mechanical ventilation postoperatively, good recovery of spontaneous respiration and emergence are importent. We evaluated emergence status in patients who were underwent P/D with desflurane (DES) anesthesia in the clinical settings. Method: Records of consecutive patients at our hospital who were underwent P/D from May 2013 to January 2018 and lung lobectomy via thoracotomy from June 2016 to August 2017 were collected. Patients anesthetized with DES were investigated. Lobectomy with chest wall resection were excluded. P/D group (n¼19) and control group (n¼20) were analyzed. General anesthesia was maintained with DES (3-5%), remifentanil, and rocronium combined with epidural anesthesia. Administration of DES was abruptly discontinued jist after postoperative X-ray examination. A patient was extubated after sugamadex was injected. Extubation time (T1) was defined as duration from the end of operation to extubation. Continuous variables were expressed as median and interququartile range (IQR). Fisher's exact test and Mann-Whitney U-tests were used for statistical analysis.
Result: There were no significant difference in demographic data (age, gender, BMI, PaO2, Hb, ALB) between the two groups, except for %VC and FEV1%. All patients were extubated after surgery. There was no significant difference in T1 between the two groups. Despite significantly larger amount of blood loss, longer operation and anesthesia time in the P/D group, time independent recovery of DES was achieved as same as the control group. Conclusion: This retrospective clinical study shows good emergence and recovery following prolonged desflurane anesthesia. Desflurane is a useful agent for patients underwent P/D. The findings from this study will provide scientific foundation for future design of clinical trials of DFMO for adjuvant therapy in early disease for advanced MPM. Method: Nude mice were fed with DFMO in drinking water 7 days before subcutaneous inoculation of 200,000 tumor cells (211H (biphasic) or H226 (epithelioid)). Mice with tumor size >600mm3 were considered reaching humane endpoint. Spermidine levels, protein expression, cytokines concentrations, NFkB translocation and apoptosis were investigated by Dot plot, Western blot, ELISA, immunofluorescence staining and TUNEL assay respectively. Result: DFMO suppressed tumor growth in both xenografts. DFMO increased median survival from 49.5 days in control arm to 65 days in treatment arm in mice with 211H xenografts (p ¼ 0.08), while from 44 days to 120 days in those with H226 xenografts (p ¼ 0.0002). In H226 xenograft model, 43% of treated mice have not yet reached humane endpoint, mimicking long-term survival. Upon DFMO treatment, decrease in spermidine level, increase in nitrotyrosine content, nuclear translocation of NFkB, elevation of serum IL-6 and activation of apoptosis were observed in both xenografts. In addition, increase in nitrocysteine level, decrease in serum keratinocyte chemoattractant (KC), increase in serum TNF alpha, elevation of DNA lesion and inhibition of Akt/mTOR pathway were induced by DFMO in H226 xenografts, which may explain higher potency of DFMO in this xenograft. 
